Replies to post #238779 on Biotech Values

[DewDiligence]

ABT 2Q21 Results by Business Segment

 
                  %Corp      YoY Growth  
 Segment          Sales   (const currency) 
 Medical devices*  36%       +45%   
 Diagnostics       32%       +57%   
 Nutrition         21%       +10%   
 Drugs†            12%       +15%

2Q21 COVID-19 diagnostics sales were $1.5B, 46% of total 2Q21 diagnostics sales.

65% of overall corporate sales were ex-US.

*Includes diabetes care.
†Branded generics in emerging markets.